The Clinical Efficacy, Safety, and Tolerability of Vancomycin for the Treatment of Recurrent Clostridioides difficile Infection - A Systematic Review.

Maja Johanne Søndergaard Knudsen Ingrid Maria Cecilia Rubin Andreas Munk Petersen

Published in: Drug, healthcare and patient safety (2023)

While oral vancomycin is mostly safe and well tolerated in the RCTs reviewed here, the efficacy for treating rCDI varies greatly from 19-58.3%, and 50-63% of participants experienced new episodes of rCDI.

Keyphrases

methicillin resistant staphylococcus aureus
clostridium difficile
open label
clinical trial
combination therapy
randomized controlled trial